A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
about
Pathway analysis for drug repositioning based on public database miningBET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapyCharacterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumorsPreoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer.Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissuesMolecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.COX-2 modulates mammary tumor progression in response to collagen density.Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.Punica granatum and its therapeutic implications on breast carcinogenesis: A review.Role of Aspirin in Breast Cancer Survival.Synergistic drug combinations from electronic health records and gene expression.Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis.Celecoxib affects estrogen sulfonation catalyzed by several human hepatic sulfotransferases, but does not stimulate 17-sulfonation in rat liver.The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.Novel strategy for cystitis glandularis: Oral treatment with cyclooxygenase-2 inhibitor.Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density.Celecoxib in breast cancer prevention and therapy
P2860
Q28657698-1DFF398A-13E0-496F-9BCF-DAC96FD16824Q30248629-9F07D297-0098-480A-9B27-52B8AA46283CQ33702468-3B4AF0FA-6EF2-4043-961D-B9FF4A939B17Q33913432-532634A2-8B47-4E78-9281-DDE116247EFFQ34369331-44D926C2-5E6F-4169-9BFA-35DE3BCC58EBQ34432882-AA37E382-0403-4D9C-AE6B-3179C3237814Q34996098-0D575C01-28A8-4AA4-8D15-898B9152E9FDQ35273633-66EEF77C-84AD-46D2-A3BB-A7CCF00A2D0EQ35820816-C36ADBBD-7F2F-4AB6-948D-80014AB4A404Q36420170-629BDBD7-B2B1-498E-BD56-006D7897ECB1Q36715145-9AA8538B-B129-4DB4-A191-87989AFE1DEAQ37072929-3E2AE333-3CFF-46CF-97AC-239453A431FAQ38379632-21CC0326-36AB-41EA-9566-45B3759DA123Q38413188-C6750CB2-D507-4C91-991E-CCC273C09168Q38735032-396BF826-0ED2-4350-BAA2-1A26DA5E9127Q39111678-32251AAF-D014-4BB2-A0D2-FBD9376C45FFQ40814411-7D8ECA32-2F32-46BB-99B4-7E507DD9A8B3Q40836898-91C4F814-EF3D-4D5F-A17E-363ECD1A2E5FQ42561379-2F67EFE0-B675-4660-BC35-FDD1122948D1Q44586148-9F74C169-5163-40F5-A0CB-9CD70B2FE3F8Q46359743-0DE2F928-63CF-4A41-95CB-39F32A357731Q47273449-28D36A6A-81DE-453E-9F4F-F5110D5184EEQ50848306-792CA15E-87EA-4373-BF0F-B4510E4E5F05Q50893711-A13D290E-8344-4735-8822-7AD45F090E22Q53400538-508AF5B9-4388-4ADD-96AE-3FD2C39750A7Q59135502-D8CD4D44-CFBD-4039-A29D-AEF78AF2E62B
P2860
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A randomised controlled phase ...... onse in primary breast cancer.
@en
type
label
A randomised controlled phase ...... onse in primary breast cancer.
@en
prefLabel
A randomised controlled phase ...... onse in primary breast cancer.
@en
P2093
P2860
P356
P1476
A randomised controlled phase ...... onse in primary breast cancer.
@en
P2093
Bart de Vries
Catharina H M J van Elssen
Hubert J M Smeets
Koen K Van de Vijver
Kristien Keymeulen
Marinus J Blok
Patrick Lindsey
Pierre S Hupperets
Rita D Brandão
Torik Ayoubi
P2860
P2888
P356
10.1186/BCR3409
P50
P577
2013-04-08T00:00:00Z
P5875
P6179
1018407370